Dr Reddy’s hits 52-week high as USFDA flags 7 points

Stock jumps to fresh 52-week high

Shares of Dr Reddy’s Laboratories rose sharply on Monday, hitting a fresh 52-week high of ₹1,410, up 4.4% in intra-day trade, supported by strong volumes. The stock was also seen nearing its life-time high of ₹1,413, recorded in August 2024. The move kept the stock in focus as investors weighed both the price momentum and a fresh regulatory disclosure tied to the company’s biologics manufacturing site.

The stock has traded with a positive bias over the last six trading sessions, during which it has gained over 11%, according to the trading update in the provided information. At 9:46 AM, Dr Reddy’s was trading 4.1% higher at ₹1,405.

What the company disclosed to stock exchanges

Dr Reddy’s said in an exchange filing, shared after market hours on Thursday, that the US Food and Drug Administration (USFDA) completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection was conducted between June 16 and June 25, 2026.

At the end of the inspection, the USFDA issued a Form 483 with seven observations. The company said it will address the observations within the stipulated timeline. It also noted that this disclosure was in continuation of earlier inspections and related stock exchange disclosures dated October 12, 2023 and September 13, 2025.

Why Form 483 observations matter

A Form 483 is issued when USFDA investigators observe conditions that may violate the agency’s requirements. The information provided also noted that these observations are preliminary and do not represent the agency’s final determination.

Still, a Form 483 at a biologics facility draws attention because the plant is described as a key part of Dr Reddy’s biosimilar strategy. The update becomes a near-term watchpoint for investors tracking progress on manufacturing readiness and regulatory milestones.

Repeat observations keep Bachupally under scrutiny

The provided information highlighted that the same Bachupally facility has seen repeated inspection activity over the last few years. It also stated that a prior USFDA inspection at the site was a Pre-Approval Inspection (PAI) conducted between September 4 and September 12, 2025, after which the company received a Form 483 with five observations.

A comparison cited in the text pointed to a shift from 5 observations in 2025 to 7 in 2026, suggesting that the regulator remained unsatisfied with the remediation progress of prior deficiencies. Separately, the text also described the latest exercise as a 10-day inspection and flagged that the repeat nature of observations at this site could delay high-margin product approvals in the US market.

Market snapshot and what investors tracked

Despite the regulatory overhang, the stock price action remained strong on Monday. The move to ₹1,410 placed the counter close to the ₹1,413 life-time high from August 2024, while the day’s trading update showed Dr Reddy’s still holding gains around mid-morning.

The information also included a prior closing reference point: the stock advanced 1.63% to settle at ₹1,350 on Thursday, June 25, 2026. This sequence placed the USFDA update and subsequent sessions in context, with momentum extending into the new week.

Key facts at a glance

Inspection timeline and observation count

Market impact: why the disclosure can influence sentiment

The text described the near-term impact as likely to be price consolidation while the market awaits clarity on the nature of the observations. It also stated that capital allocation has been diverted into the biologics pipeline and that delays in approvals can increase the burn rate on those investments without corresponding revenue realisation.

The provided information further said that until the USFDA classifies the inspection as VAI, the biosimilar approval pipeline remains stagnant. It also mentioned that, historically, a Form 483 with seven observations can lead to 2% to 4% short-term volatility.

Broader context mentioned in the data

Beyond the Bachupally inspection, the supplied text referenced other business updates and risks. It noted a 4.4% year-on-year revenue increase (without stating an absolute revenue figure), and said the consolidated gross profit margin contracted 505 points year-on-year, linked to lower Lenalidomide sales and pricing pressure in unbranded generics.

The text also said SG&A expenditure rose 12% year-on-year due to targeted investments and unfavourable foreign exchange conditions. It additionally referenced earlier regulatory issues, including a complete response letter for a denosumab biosimilar BLA (as described in the input), underscoring that regulatory execution remains a recurring theme for investors tracking the company’s pipeline.

Conclusion

Dr Reddy’s stock strengthened to a new 52-week high even as the company disclosed a Form 483 with seven observations following a June 16 to June 25, 2026 USFDA pre-license inspection at its Bachupally biologics facility. The company has said it will respond within the stipulated timeline. The next market focus, based on the provided information, is likely to remain on updates around remediation progress and the regulatory path ahead for approvals linked to the Bachupally site.